Flashlight Therapeutics

Diagonal Therapeutics, formerly known as Flashlight Therapeutics, is a biotechnology company pioneering the development of agonist antibodies for severe diseases. The company was originally co-founded by Atlas Venture and Dr. Arvin Dar, initially exploring small molecule approaches before evolving into its current focus on immunomodulatory antibodies. Diagonal utilizes its proprietary DIAL platform, which integrates computational biology and high-throughput screening to identify antibodies that activate signaling pathways by mimicking natural ligands. The company's lead candidate, DGN-001, targets the ALK1 pathway for the treatment of hereditary hemorrhagic telangiectasia (HHT). With a pipeline that also includes programs for pulmonary arterial hypertension (PAH), Diagonal aims to restore cellular homeostasis in patients with limited treatment options. The company is currently in the pre-clinical stage and is supported by a significant Series A investment from leading life science venture firms.